{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:45:04Z","timestamp":1757454304268,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T00:00:00Z","timestamp":1559952000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T00:00:00Z","timestamp":1559952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["10.13039\/501100001659; EXC 257 NeuroCure"],"award-info":[{"award-number":["10.13039\/501100001659; EXC 257 NeuroCure"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12883-019-1339-x","type":"journal-article","created":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T10:02:33Z","timestamp":1559988153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-9785","authenticated-orcid":false,"given":"Juliane","family":"Klehmet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svenja","family":"Beutner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Dornauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Reilmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander U.","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,8]]},"reference":[{"key":"1339_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrneurol.2014.117","volume":"10","author":"N Latov","year":"2014","unstructured":"Latov N. Diagnosis and treatment of chronic acquired demyelinating polyneuropathies. Nat Rev Neurol. 2014;10:435\u201346.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"1339_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/WCO.0b013e328363bfa4","volume":"26","author":"Filip Eftimov","year":"2013","unstructured":"Eftimov F, Van S, I : chronic inflammatory demyelinating polyradiculoneuropathy: update on clinical features, phenotypes and treatment options. Curr Opin Neurol 2013, 26: 496\u2013502.","journal-title":"Current Opinion in Neurology"},{"key":"1339_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","volume":"7","author":"MC Dalakas","year":"2011","unstructured":"Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011;7:507\u201317.","journal-title":"Nat Rev Neurol"},{"key":"1339_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1212\/WNL.0000000000001833","volume":"85","author":"JA Allen","year":"2015","unstructured":"Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015;85:498\u2013504.","journal-title":"Neurology"},{"key":"1339_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jnnp-2016-314895","volume":"88","author":"H Koike","year":"2017","unstructured":"Koike H, Kadoya M, Kaida KI, Ikeda S, Kawagashira Y, Iijima M, et al. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry. 2017;88:465\u201373.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1339_CR6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1212\/WNL.0000000000006625","volume":"91","author":"H Koike","year":"2018","unstructured":"Koike H, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, et al. Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology. 2018;91:1051\u201360.","journal-title":"Neurology"},{"key":"1339_CR7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve. 1991;14:1103\u20139.","journal-title":"Muscle Nerve"},{"key":"1339_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/mus.10045","volume":"25","author":"IS Merkies","year":"2002","unstructured":"Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve. 2002;25:370\u20137.","journal-title":"Muscle Nerve"},{"key":"1339_CR9","first-page":"1","volume":"15","author":"European Federation of Neurological Societies\/","year":"2010","unstructured":"European Federation of Neurological Societies\/. Peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the peripheral nerve society--first revision. J Peripher Nerv Syst. 2010;15:1\u20139.","journal-title":"J Peripher Nerv Syst"},{"key":"1339_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/jnnp-2018-318714","volume":"90","author":"PE Doneddu","year":"2019","unstructured":"Doneddu PE, Cocito D, Manganelli F, Fazio R, Briani C, Filosto M, et al. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP database. J Neurol Neurosurg Psychiatry. 2019;90:125\u201332.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1339_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1529-8027.2010.00284.x","volume":"15","author":"KC Gorson","year":"2010","unstructured":"Gorson KC, van Schaik IN, Merkies IS, Lewis RA, Barohn RJ, Koski CL, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst. 2010;15:326\u201333.","journal-title":"J Peripher Nerv Syst"},{"key":"1339_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1006\/exnr.2000.7348","volume":"163","author":"AM Gordon","year":"2000","unstructured":"Gordon AM, Quinn L, Reilmann R, Marder K. Coordination of prehensile forces during precision grip in Huntington's disease. Exp Neurol. 2000;163:136\u201348.","journal-title":"Exp Neurol"},{"key":"1339_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/B978-0-12-801893-4.00018-3.:209-225.","volume":"144","author":"R Reilmann","year":"2017","unstructured":"Reilmann R, Schubert R. Motor outcome measures in Huntington disease clinical trials. Handb Clin Neurol. 2017;144:209\u201325. \n                    https:\/\/doi.org\/10.1016\/B978-0-12-801893-4.00018-3.:209-225.","journal-title":"Handb Clin Neurol"},{"key":"1339_CR14","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/mds.23816","volume":"26","author":"R Reilmann","year":"2011","unstructured":"Reilmann R, Bohlen S, Kirsten F, Ringelstein EB, Lange HW. Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures. Mov Disord. 2011;26:2267\u201373.","journal-title":"Mov Disord"},{"key":"1339_CR15","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1055\/s-0028-1111672","volume":"91","author":"EW Funfgeld","year":"1966","unstructured":"Funfgeld EW. The vigorimeter: for measurement of the strength of the hand and simulation testing. Dtsch Med Wochenschr. 1966;91:2214\u20136.","journal-title":"Dtsch Med Wochenschr"},{"key":"1339_CR16","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1468-1331.2012.03851.x","volume":"20","author":"EK Vanhoutte","year":"2013","unstructured":"Vanhoutte EK, Latov N, Deng C, Hanna K, Hughes RA, Bril V, et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study. Eur J Neurol. 2013;20:748\u201355.","journal-title":"Eur J Neurol"},{"key":"1339_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ana.1088","volume":"50","author":"R Hughes","year":"2001","unstructured":"Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195\u2013201.","journal-title":"Ann Neurol"},{"key":"1339_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"RA Hughes","year":"2008","unstructured":"Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136\u201344.","journal-title":"Lancet Neurol"},{"key":"1339_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1212\/WNL.57.5.920","volume":"57","author":"R Reilmann","year":"2001","unstructured":"Reilmann R, Kirsten F, Quinn L, Henningsen H, Marder K, Gordon AM. Objective assessment of progression in Huntington's disease: a 3-year follow-up study. Neurology. 2001;57:920\u20134.","journal-title":"Neurology"},{"key":"1339_CR20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","volume":"8","author":"SJ Tabrizi","year":"2009","unstructured":"Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8:791\u2013801.","journal-title":"Lancet Neurol"},{"key":"1339_CR21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013;12:637\u201349.","journal-title":"Lancet Neurol"},{"key":"1339_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/mds.26174","volume":"30","author":"R Reilmann","year":"2015","unstructured":"Reilmann R, Rouzade-Dominguez ML, Saft C, Sussmuth SD, Priller J, Rosser A, et al. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Mov Disord. 2015;30:427\u201331.","journal-title":"Mov Disord"},{"unstructured":"Reilmann R, McGarry A, Granchev I, Savola JM, Borowsky B, Eyal E, et al. Efficacy and safety of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomized, placebo-controlled, multicentre dose-ranging study. Lancet Neurol. 2018; in press.","key":"1339_CR23"},{"key":"1339_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12883-015-0517-8","volume":"15","author":"S Hoffmann","year":"2015","unstructured":"Hoffmann S, Siedler J, Brandt AU, Piper SK, Kohler S, Sass C, et al. Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study. BMC Neurol. 2015;15:265.","journal-title":"BMC Neurol"},{"key":"1339_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.932","volume":"8","author":"JA Allen","year":"2018","unstructured":"Allen JA, Gorson KC, Gelinas D. Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy. Brain Behav. 2018;8:e00932.","journal-title":"Brain Behav"},{"issue":"3","key":"1339_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/jns.12126","volume":"20","author":"Thomas H. P. Draak","year":"2015","unstructured":"Draak TH, Pruppers MH, van Nes SI, Vanhoutte EK, Bakkers M, Gorson KC et al.: Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar J Peripher Nerv Syst 2015, 20: 269\u2013276.","journal-title":"Journal of the Peripheral Nervous System"},{"key":"1339_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/mus.26136","volume":"58","author":"KL Knak","year":"2018","unstructured":"Knak KL, Andersen LK, Christiansen I, Markvardsen LK. Does grip strength reflect isokinetic muscle strength in lower limbs in patients with chronic inflammatory demyelinating polyneuropathy? Muscle Nerve. 2018;58:449\u201352.","journal-title":"Muscle Nerve"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1339-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-019-1339-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1339-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T23:03:24Z","timestamp":1591484604000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-019-1339-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,8]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1186\/s12883-019-1339-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2019,6,8]]},"assertion":[{"value":"12 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee of the Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin (EA1\/025\/11). All patients gave written informed consent in accordance with the Declaration of Helsinki in its currently applicable form. This consent was signed by the patient if possible, or by a third person in the presence of the full conscientious patient. These criteria were approved by the ethics committee. Any patient in this study was able to provide written informed consent due their condition.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J Klehmet received speaker\u2019s honoraria and travels grants from Grifols, Octapharma, CSL Behring, Novartis, Bayer and Merck. S Beutner, S Hoffmann, M Dornauer, and A Meisel declare no competing interests. F Paul serves on the scientific advisory board for Novartis; received speaker honoraria and travel funding from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis\/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is an academic editor for <i>PLoS ONE<\/i>; is an associate editor for <i>Neurology<\/i>\u00ae <i>Neuroimmunology & Neuroinflammation<\/i>; consulted for SanofiGenzyme, Biogen Idec, MedImmune, Shire, and Alexion; and received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis\/Genzyme, Alexion, Merck Serono, German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, and National Multiple Sclerosis of the USA. R Reilmann is founding director and owner of the George-Huntington-Institute, a private research institute focused on clinical and preclinical research in Huntington\u2019s disease, and QuantiMedis, a clinical research organization providing Q-Motor (quantitative motor) services in clinical trials and research. He holds appointments at the Dept. of Radiology of the University of Muenster and at the Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of Tuebingen. Dr. Reilmann serves as elected member of the Steering Committees of the European Huntington Disease Network (EHDN) and the Huntington Study Group (HSG), co-chair of the Task Force on Huntington\u2019s disease and member of the Task Force on Technology of the International Parkinson and Movement Disorder Society (IPMDS). He has provided consulting services, advisory board functions, clinical trial services, quantitative motor analyses, and\/or lectures for Actelion Pharmaceuticals, Amarin Neuroscience, AOP Orphan Pharmaceuticals, Cure Huntington Disease Initiative Foundation (CHDI), Desitin, Hoffmann-La Roche, IONIS Pharmaceuticals, Ipsen, Lundbeck, Link Medicine, MEDA Pharma, Medivation, Mitoconix, Neurosearch, Novartis AG, Omeros, Pfizer, Prana Biotechnology, Prilenia, Raptor Pharmaceuticals, Siena Biotech, Temmler Pharma, Teva Pharmaceuticals, uniQure, Vaccinex, Wave Life Sciences, and Wyeth Pharmaceuticals. He has received grant support from the Bundesministerium f\u00fcr Bildung und Forschung (BMBF), the Cure Huntington Disease Initiative Foundation (CHDI), the Deutsche Forschungsgemeinschaft (DFG), the Deutsches Zentrum f\u00fcr Neurodegeneration und Entz\u00fcndung (DZNE), the European Union 7th Framework Program (EU-FP7), the European Huntington Disease Network (EHDN), the High-Q-Foundation, and the National Science Foundation (NSF). A U Brandt is cofounder and shareholder of technology companies Motognosis GmbH and Nocturne GmbH. He is named as inventor on several patent applications describing serum biomarkers in multiple sclerosis, perceptive visual computing based motion analysis and retinal image analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}